BURR
RIDGE, Ill., May 1, 2024
/PRNewswire/ -- SkinCure Oncology, the world leader in providing a
comprehensive model for the delivery of Image-Guided Superficial
Radiation Therapy (Image-Guided SRT, or the GentleCure™
Experience), the most advanced nonsurgical treatment for common
skin cancer, today announced survey results showing a sharp
difference in how patients treated for common skin cancer feel
about their surgical versus nonsurgical procedures.
The survey involved 3,915 individuals who had been treated for
nonmelanoma skin cancer one or more times. Eighty-six percent said
they were happy with their choice of Image-Guided SRT, while only
24 percent said they were happy with their choice of Mohs surgery.
Asked if they would recommend their treatment to a friend or loved
one, 83 percent said yes about Image-Guided SRT, while 13 percent
said the same for surgery.
SkinCure Oncology Chief Executive Officer Kerwin Brandt explained, "With GentleCure, we're
providing cancer center level of care in the private practice.
There are relatively few Mohs surgeons in the U.S., and they're
especially rare in rural America, so providing this option in the
local dermatology practice is a potential life-saver for many."
Dermatologists across the country are celebrating the
introduction of this nonsurgical treatment for the nation's most
common cancer type – nonmelanoma skin cancer. While May is Skin
Cancer Awareness Month, early-adopter skin specialists in 40 states
are already providing the GentleCure Experience to patients who
prefer to avoid surgery or for whom surgery is not recommended.
The GentleCure Experience involves the use of low-level x-rays,
precisely targeted with high-definition ultrasound imaging, to
destroy cancer cells. The painless procedure, which only takes
minutes, is repeated over a series of visits to the dermatologist's
office. This newer, noninvasive option produces the same 99%+ cure
rate as traditional Mohs surgery, with none of the pain or surgical
scarring that often accompanies that nearly century-old
procedure.
CEO Brandt added, "It is absolutely essential for patients to
have information on all available treatment options, both surgical
and nonsurgical, so they can make informed decisions about their
care. Image-Guided SRT is the most exciting technological
innovation in dermatology today."
To date, five governors and a host of mayors have issued formal
proclamations celebrating nonmelanoma skin cancer awareness weeks
coinciding with first-in-state and -county offerings of
Image-Guided SRT. Kentucky
Governor Andy Beshear, in his
proclamation last Fall, noted, "Some 3.3 million people in
the United States are diagnosed
with nonmelanoma skin cancer each year," and those individuals
"should discuss their treatment options with their doctors and
other healthcare providers in a timely fashion. The Commonwealth of
Kentucky … encourages its citizens
to learn about risk factors, preventive strategies and available
treatment options."
For more information about the GentleCure Experience and
assistance in finding a provider near you, visit
GentleCure.com.
About SkinCure Oncology
SkinCure Oncology is the world leader in providing a
comprehensive model for the delivery of Image-Guided Superficial
Radiation Therapy (Image-Guided SRT), the most advanced nonsurgical
treatment for common skin cancer. The company partners with
quality-focused dermatologists, Mohs surgeons and other physicians
to bring cancer center-level radiation therapy treatment to private
practices. Presented to patients as the GentleCure™ experience,
Image-Guided SRT is available from some 500 physicians nationwide,
with more than 75,000 patients having been treated. Learn more
about the company at SkinCureOncology.com, and
visit GentleCure.com for helpful consumer and patient
information.
Media Contact:
Matt
Russell
Russell Public Communications
520-232-9840
mrussell@russellpublic.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/survey-shows-stark-difference-in-satisfaction-rates-among-skin-cancer-patients-treated-surgically-and-nonsurgically-302133368.html
SOURCE SkinCure Oncology